BrainsWay raises $45M Series D for deep TMS global expansion following OCD real-world data

Summary

Israel-based BrainsWay secured $45M Series D led by Pontifax, with aMoon Partners and Peregrine Ventures, following publication of real-world 52% OCD remission data across 847 patients. The round will fund US sales force expansion from 80 to 150 representatives and EU direct sales entry in Germany, France, and the UK.